RT Journal Article
SR Electronic
T1 Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21261175
DO 10.1101/2021.09.06.21261175
A1 Bhuiyan, Md S.
A1 Brintz, Ben J.
A1 Whitcombe, Alana L.
A1 Markmann, Alena J.
A1 Bartelt, Luther A.
A1 Moreland, Nicole J.
A1 Azman, Andrew S.
A1 Leung, Daniel T.
YR 2021
UL http://medrxiv.org/content/early/2021/09/08/2021.09.06.21261175.abstract
AB Serosurveillance is an important epidemiologic tool for SARS-CoV-2, used to estimate burden of disease and degree of population immunity. Which antibody biomarker, and the optimal number of biomarkers, has not been well-established, especially with the emerging rollout of vaccines globally. Here, we used random forest models to demonstrate that a single spike or receptor-binding domain (RBD) antibody was adequate for classifying prior infection, while a combination of two antibody biomarkers performed better than any single marker for estimating time-since-infection. Nucleocapsid antibodies performed worse than spike or RBD antibodies for classification, but is of utility for estimating time-since-infection, and in distinguishing infection-induced from vaccine-induced responses. Our analysis has the potential to inform the design of serosurveys for SARS-CoV-2, including decisions regarding number of antibody biomarkers measured.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institutes of Health (R01 AI135115 to D.T.L.), with funding in part from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health, through Grant UL1TR002538 (formerly 5UL1TR001067-05, 8UL1TR000105 and UL1RR025764).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This analysis was reviewed by the Institutional Review Board of the University of Utah and determined to not meet definitions of Human Subjects Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data will be deposited on github upon publication.